0000-0003-0473-4901 Employment
-
Neomatrix biotech Chief scientific officer2020 - Present
-
Takis biotech2015 - Present
-
CHUV2010 - Present
-
Alleanza Contro il Cancro1995 - Present
-
IRBM a subsidiary site of Merck (MSD)1992 - Present
-
MIT1987 - Present
-
Istituto Superiore di Sanità1987 - Present
-
Sapienza University of Rome1984 - Present
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (66)
- Synthetic DNA vaccine platform elicits potent immunity where electroporated naked-mRNA is non-immunogenic. Save
- Intramuscular plasmid DNA electroporation sequesters neoantigen-specific CD8+ T cells in treated muscle and limits tumor infiltration Save
- Immunogenicity of COVID-eVax Delivered by Electroporation Is Moderately Impacted by Temperature and Molecular Isoforms Save
- A linear DNA vaccine candidate encoding the SARS-CoV-2 Receptor Binding Domain elicits protective immunity in domestic cats Save
- DNA-Vaccine-Induced Immune Response Correlates with Lower Viral SARS-CoV-2 Titers in a Ferret Model Save
- Linear DNA amplicons as a novel cancer vaccine strategy Save
- Neoantigen cancer vaccine augments anti-CTLA-4 efficacy Save
- COVID-eVax, an electroporated plasmid DNA vaccine candidate encoding the SARS-CoV-2 Receptor Binding Domain, elicits protective immune responses in animal models of COVID-19 Save
- Antitumor efficacy of a neoantigen cancer vaccine delivered by electroporation is influenced by microbiota composition Save
- SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines Save